| Company | Value | Change | %Change |
|---|
The drug maker’s revenue grew 12.3% to ₹1,614.3 crore, supported by a stable demand environment across its product portfolio.
The company’s operating profit also saw an improvement, with EBITDA increasing 12.5% to ₹436.2 crore from ₹387.7 crore a year ago.
Margins remained steady at 27%, reflecting stable input costs and operating efficiencies.Also read: Zydus Lifesciences Q3 Results: US formulation sales near $300 million, forex gains aid profit
The company continues to focus on its core pharmaceutical and healthcare businesses, which have contributed to its sustained performance.
Shares of Abbott India surged 6.13% higher at ₹27,745 on the BSE on Tuesday. The pharma stock reacted positively to the results, with investor sentiment remaining strong.
